cGMPnow

Executive Summary

cGMPnow is a San Diego-based service provider specializing in accelerating the development and manufacturing of next-generation therapies, including cell and gene therapies. Founded in 2015, the company offers a comprehensive suite of GxP-compliant services: manufacturing and QC laboratory equipment, computerized systems, commissioning and qualification, and procurement—all delivered through project-dedicated expert resources. By addressing critical bottlenecks in facility setup, regulatory compliance, and equipment integration, cGMPnow enables biotech and pharmaceutical clients to reduce time-to-clinic and time-to-market. The company positions itself as a one-stop partner for modular, scalable solutions, particularly valuable for emerging therapy developers lacking in-house GxP expertise. As the cell and gene therapy field matures and manufacturing capacity expands, cGMPnow is poised to benefit from increased outsourcing of specialized compliance and validation services. However, as a private company with limited public financial disclosure, its growth trajectory and competitive moat are difficult to assess. Overall, cGMPnow occupies a niche but essential role in the life sciences supply chain, with potential for steady revenue growth driven by industry tailwinds.

Upcoming Catalysts (preview)

• Q1 2026Announcement of Major Contract with Cell Therapy Developer70% success
• Q3 2026Expansion of Service Offerings into Viral Vector Manufacturing Support50% success
• Q4 2026Partnership with CDMO to Provide Integrated GxP Compliance Solutions60% success